Crystal forms of β-nicotinamide mononucleotide
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
1. A method of determining XRPD pattern of a crystalline form of a compound having the structure of formula (I),
or a salt thereof, wherein the crystalline form is Form 2, having 20 values 8.29; 17.39; 19.54; 22.78; and 22.98, and wherein the method comprises:
providing the crystalline form of a compound having the structure of formula (I),
exposing the crystalline form of a compound having the structure of formula (I) to X-Rays, and
recording intensities and scattering angles of the X-Rays.
2. The method of claim 1 , wherein the crystalline form is Form 2, having 2θ values 8.29; 17.39; 19.54; 19.74; 20.98; 21.58; 22.03; 22.78; 22.98; and 25.53.
3. The method of claim 1 , wherein the crystalline form is Form 2, having 2θ values 8.29; 16.10; 17.39; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 25.53; 28.48; and 29.48.
4. The method of claim 1 , wherein the crystalline form is Form 2, having 2θ values 8.29; 13.12; 15.79; 16.10; 16.69; 17.39; 19.03; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 23.95; 24.14; 24.48; 24.64; 25.14; 25.53; 25.87; 26.89; 27.18; 27.67; 28.02; 28.13; 28.48; 28.98; 29.34; 29.48; and 29.92.
5. The method of claim 1 , wherein the crystalline form is Form 2, having an XRD pattern substantially as shown in FIG. 1 , labeled Form 2.
6. A method of determining XRPD pattern of a crystalline form of a compound having the structure of formula (I),
or a salt thereof, wherein the crystalline form is Form 1, having 2θ values 20.03; 20.14; 21.83; and 25.73, and wherein the method comprises:
providing the crystalline form of a compound having the structure of formula (I),
exposing the crystalline form of a compound having the structure of formula (I) to X-Rays, and
recording intensities and scattering angles of the X-Rays.
7. The method of claim 6 , wherein the crystalline form is Form 1, having 2θ values 20.03; 20.14; 21.03; 21.83; 23.08; 23.39; 25.73; and 26.59.
8. The method of claim 6 , wherein the crystalline form is Form 1, having 2θ values 7.70; 11.54; 12.64; 16.03; 18.99; 20.03; 20.14; 20.83; 21.03; 21.83; 23.08; 23.39; 25.48; 25.73; 26.59; and 29.78.
9. The method of claim 6 , wherein the crystalline form is Form 1, having 2θ values 7.70; 9.95; 11.54; 12.64; 16.03; 18.18; 18.99; 19.16; 19.44; 20.03; 20.14; 20.83; 21.03; 21.83; 22.44; 23.08; 23.39; 23.89; 24.08; 24.53; 24.68; 25.05; 25.48; 25.73; 26.08; 26.59; 27.33; 27.67; 29.78; and 29.92.
10. The method of claim 6 , wherein the crystalline form wherein the crystalline form is Form 1, having an XRD pattern substantially as shown in FIG. 1 , labeled Form 1.